Stellungnahme der DGVS zur frühen Nutzenbewertung von Tofacitinib

Raja Atreya, Erlangen
Niels Teich, Leipzig

• Literatur

• 1 Dignass A, Lindsay JO, Sturm A. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn’s & colitis 2012; 6: 991-1030
• 2 Kucharzik T. et al. Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) – AWMF Registry 021/009. Z Gastroenterol 2018; 56: 1087-1169
• 3 Preiß JC, Bokemeyer B, Buhr HJ. et al. Aktualisierte S3 Leitlinie „Diagnostik und Therapie des Morbus Crohn“ 2014. Zeitschrift fur Gastroenterologie 2014; 52: 1431-1484
• 4 Burisch J. et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7: 322-337
• 5 Ng SC, Shi HY, Hamidi N. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 27
• 6 Ungaro R, Mehandru S, Allen PB. et al. Ulcerative colitis. Lancet 2017; 389: 1756-1770
• 7 Molodecky NA. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54
• 8 Siegmund B, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol 2011; 17: 3178-3183
• 9 Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012; 61: 918-932
• 10 Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078
• 11 Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Alimentary pharmacology & therapeutics 2011; 33: 987-995
• 12 Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. The American journal of gastroenterology 2009; 104: 760-767
• 13 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265 e1-e3
• 14 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2005; 353: 2462-2476
• 15 Reinisch W, Sandborn WJ, Hommes DW. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787
• 16 Van Assche G, Dignass A, Bokemeyer B. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. Journal of Crohn’s & Colitis 2013; 7: 1-33
• 17 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2013; 369: 699-710
• 18 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-342
• 19 Sandborn WJ, Ghosh S, Panes J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624
• 20 Sandborn WJ, Su C, Sands BE. et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376: 1723-1736